Weight
Tirzepatide
Weekly injection
Weight management
Compounded Semaglutide
Clinically studied GLP-1 for sustained, medically guided weight loss.
Medical guidance
Clinical review required
Availability and treatment are not guaranteed.
vidameds
Compounded medications are not FDA-approved.
Understanding Semaglutide
Know the treatment.
Ask better questions.
Semaglutide is a GLP-1 receptor agonist used in approved formulations for specific diabetes or weight-management indications. This listing depicts a compounded product, not an FDA-approved brand.
How it works
It acts on GLP-1 receptors involved in appetite and blood sugar regulation. Weight-management care typically combines medication with nutrition and physical activity.
Safety & suitability
Common side effects include nausea, vomiting, diarrhea, and constipation. Serious risks include pancreatitis and gallbladder problems. Certain thyroid cancer histories, pregnancy, and other conditions may rule out treatment.
Bring to your care conversation
- Which approved alternatives fit my history, and why would a compounded option be considered?
- What is the exact formulation, and which approved alternatives should I consider?
- What side effects, interactions, and follow-up should we discuss before a decision?
Research, in perspective
What the evidence says.
A substantial trial. A specific formulation.
In STEP-1, adults with obesity, or overweight with a weight-related condition, without diabetes received a studied semaglutide injection or placebo alongside lifestyle support. Average weight reduction at 68 weeks was 14.9% with semaglutide and 2.4% with placebo.
The study used semaglutide 2.4 mg weekly—not the compounded product shown here. Its findings cannot confirm this product's safety, quality, or effectiveness. Clinical eligibility and current compounding rules require review.
Read the sourcesSTEP-1 · 2021
Average body-weight reduction
Adults with obesity or overweight plus a weight-related condition, without diabetes.
1,961 participants68 weeks
0–25% scale · Both groups received lifestyle support
01
GLP-1 receptor activity
02
Appetite and blood-glucose regulation
03
Clinical response varies with treatment and individual factors
Sources & further reading
- 01STEP-1: Once-weekly semaglutide in adults with overweight or obesity (2021)
- 02FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Research context is educational and does not confirm the safety, effectiveness, or availability of the pictured product.
The Vida Meds difference
Connected care.
Personal at every step.
A nationwide provider network. Direct pharmacy pricing. A team you can reach.
200+
Licensed providers
A nationwide network of licensed clinicians.
50 states
Nationwide care
Our provider network spans all 50 states.
Direct pharmacy
Pricing
Direct Pharmacy Pricing for your treatment.
Overnight
ColdChain Shipping
Temperature-controlled shipping for medications that require it.
24-hour
Customer support
Support for your questions, around the clock.
Direct access
Patient portal
Connect with your provider and dedicated care team.
Treatment eligibility, medication availability, and shipping arrangements depend on clinical review and the prescribed medication. Customer support is not emergency care; call 911 for a medical emergency.
Beyond the medication
A healthier weight. A fuller life.
Explore GLP-1 treatment alongside nutrition, movement, and medical guidance. The right approach starts with your health history—not a one-size-fits-all plan.
Explore weight management
